header logo nl


10 facts web


Savolitinib vs Sunitinib in MET-driven Papillary Renal Cell Carcinoma
 Phase 3; 180 patients
 Last updated: April 09, 2018
 STATUS: Recruiting (accepting new patients) (per https://clinicaltrials.gov/NCT03091192)


is the trial for?

Patients with papillary kidney cancer (papillary renal cell carcinoma, PRCC) who currently meet the following criteria:
  • confirmed papillary histology
  • confirmation of MET-driven papillary renal cell carcinoma without co-occurring Fumarate Hydratase or Von Hippel Lindau mutations
  • metastatic or locally advanced disease
  • no prior therapy OR may have received prior systemic therapy for advanced or metastatic papillary renal cell carcinoma
  • Note: prior treatment cannot include a MET-inhibitor or sunitinib.


is the key question that this trial is attempting to answer?

The purpose of this phase 3 trial is to compare an investigational new anti-cancer medication for papillary kidney cancer against a standard treatment in patients whose papillary kidney cancer has spread from where it started to nearby tissue or lymph nodes or to other places in the body.

The study compares the new medication savolitinib with another medication frequently used to treat kidney cancer called sunitinib,


patients might want to participate?

This clinical trial offers patients an opportunity to access a new therapy that may be effective for papillary kidney cancer. This trial will further support the research in papillary kidney cancer and potentially help other patients with this type of kidney cancer. The trial might or might not have benefit in your individual case. For more about the importance and benefits of joining clinical trials, please click here.


will the trial be open?

The study is open (recruiting) – 180 patients are currently expected to participate.


is the trial available?

The trial will be available in various cancer centers in the USA.
For a complete list of trial locations, please click here:
Trial locations Savoir



What does the study look like?

There will be 2 study arms (groups): all participating patients will be randomly divided (by a computer) into two groups. Please note that patients in all groups will receive an active medication. No patient will receive a placebo.

Patients in group 1 will be assigned savolitinib. Patients in group 2 will be treated with sunitinib (SutentTM)
  • savolitinib is an experimental small molecule inhibitor of c-Met
  • sunitinib (Sutent™) is an oral, small-molecule, multi-targeted receptor tyrosine kinase inhibitor, already approved for the treatment of metastatic RCC
Savoir trial

1.) Savolitinib is taken by mouth once daily with food, continuously

2.) Sunitinib is taken by mouth once daily for 4 weeks then 2 weeks off.


do I get more information?

Patient organisations supporting kidney cancer patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving kidney cancer patients. If there are no such organisations in your country, please email us for more information: Dit e-mailadres wordt beveiligd tegen spambots. JavaScript dient ingeschakeld te zijn om het te bekijken.


with other patients on this trial

If you want to connect with other patients considering or participating in this trial, you can find them here: List of organisations worldwide.


your experience 

If you would like to share your experience on this trial, send us an e-mail to:Dit e-mailadres wordt beveiligd tegen spambots. JavaScript dient ingeschakeld te zijn om het te bekijken.
Note that your experience would be helpful for other patients and patient organisations.


of the study

No results are available at this time. Future results will be linked here.
Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.
Back to clinical trials overview: How can I find a clinical trial for kidney cancer?